Johnson & Johnson agreed to buy eye disease biotech Ollin for $2.2 billion upfront
Blackstone Life Sciences will pay $750 million to fully fund Phase 3 development of Ollin's lead drug candidate, OLN324
We haven't written up this one. Quartz has the full story — the link below goes straight to it.